Mylan N.V. (NASDAQ:MYL) : 7 investment research analysts covering Mylan N.V. (NASDAQ:MYL) have an average price target of $59.14 for the near short term. The highest target price given by the Brokerage Firm to the stock is $71 and the lowest target is $51 for the short term. Analysts expect the variance to be within $7.47 of the average price.
Mylan N.V. has lost 6.33% in the last five trading days and dropped 2.74% in the last 4 weeks. Mylan N.V. has dropped 8.97% during the last 3-month period . Year-to-Date the stock performance stands at -20.03%. Also, Brokerage firm Leerink Swann maintains its rating on Mylan N.V. (NASDAQ:MYL). As per the latest information, the brokerage house lowers the price target to $51 per share from a prior target of $53. The shares have been rated Outperform. The rating by the firm was issued on May 4, 2016.
Mylan N.V. (NASDAQ:MYL) has an average broker rating of 2, which is interpreted as a Buy, as rated by 10 equity analysts. Nonetheless, 5 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 5 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Mylan N.V. (NASDAQ:MYL): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $43.25 and $42.47 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $43.37. The buying momentum continued till the end and the stock did not give up its gains. It closed at $43.24, notching a gain of 0.05% for the day. The total traded volume was 7,206,393 . The stock had closed at $43.22 on the previous day.
In an insider trading activity, Maroon Joseph C Md, director of Mylan N.V. had purchased 1,670 shares on June 3, 2016 in a transaction. The price per share was $44.95 and the total amount of the disclosed transaction was $75,067.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.
Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.